glycopyrrolate/donepezil (RVT-103) / Roivant - LARVOL DELTA

Axovant Sciences announces dementia pipeline updates and reports financial results for the third fiscal quarter and nine months ended December 31, 2016 (PRNewswire) - "The company expects the following top-line results from its ongoing clinical studies in 2017: MINDSET: Results from the Phase 3 MINDSET study in the third quarter of 2017. HEADWAY-DLB: Results from the Phase 2b study of intepirdine in patients with dementia with Lewy bodies (DLB), the HEADWAY-DLB study, in the fourth quarter of 2017....Results from the RVT-103 program in the first half of 2017."

Anticipated clinical data • Anticipated P2b data • Anticipated P3 data: top line • Alzheimer's Disease